Talis Biomedical Corp
Talis Biomedical Corporation does not have significant operations. Previously, it was involved in the development of medical devices for infectious diseases and other conditions at the point of care in the United States. The company evaluates strategic alternatives, including acquisition, merger, reverse merger, divestiture of assets, a voluntary reorganization, dissolution or liquidation, and li… Read more
Talis Biomedical Corp (TLIS) - Total Assets
Latest total assets as of June 2024: $72.70 Million USD
Based on the latest financial reports, Talis Biomedical Corp (TLIS) holds total assets worth $72.70 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Talis Biomedical Corp - Total Assets Trend (2018–2023)
This chart illustrates how Talis Biomedical Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Talis Biomedical Corp - Asset Composition Analysis
Current Asset Composition (December 2023)
Talis Biomedical Corp's total assets of $72.70 Million consist of 82.1% current assets and 18.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.1% |
| Accounts Receivable | $50.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Talis Biomedical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Talis Biomedical Corp's current assets represent 82.1% of total assets in 2023, unchanged from 82.1% in 2018.
- Cash Position: Cash and equivalents constituted 81.1% of total assets in 2023, up from 60.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Talis Biomedical Corp Competitors by Total Assets
Key competitors of Talis Biomedical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Talis Biomedical Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Talis Biomedical Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Talis Biomedical Corp is currently not profitable relative to its asset base.
Talis Biomedical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.76 | 11.01 | 5.97 |
| Quick Ratio | 7.76 | 10.90 | 5.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $55.41 Million | $ 92.70 Million | $ 20.07 Million |
Talis Biomedical Corp - Advanced Valuation Insights
This section examines the relationship between Talis Biomedical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.11 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -44.1% |
| Total Assets | $94.67 Million |
| Market Capitalization | $2.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Talis Biomedical Corp's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Talis Biomedical Corp's assets decreased by 44.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Talis Biomedical Corp (2018–2023)
The table below shows the annual total assets of Talis Biomedical Corp from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $94.67 Million | -44.08% |
| 2022-12-31 | $169.29 Million | -36.32% |
| 2021-12-31 | $265.83 Million | +33.98% |
| 2020-12-31 | $198.41 Million | +671.01% |
| 2019-12-31 | $25.73 Million | +126.16% |
| 2018-12-31 | $11.38 Million | -- |